Molecular Photoswitches
A comprehensive overview about the emerging field of photoswitches and their applications in materials science and biology
Chemistry
Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development
Focused on quality by design concepts, this must-have reference for researchers in industry and academia describes theoretical basics of polymorphism and analytical characterization techniques as well as patent issues.
Dow Sells its 50% Ownership in DowAksa
Dow announced that it has signed a sale and purchase agreement to sell its 50% interest in DowAksa to Aksa Akrilik Kimya Sanayii A.Ş., a company of Akkök Holding.
Q1 2025 Chemical Industry: Diverging Trends
The first quarter of 2025 highlights a continued divergence between the European and US chemical industries.
Powering Progress: An AI-ready Data Strategy to Drive More Efficient Innovation
Build an AI-ready Data Strategy to Drive Faster Insights, Smarter R&D, and Measurable ROI.
Mitsui Chemicals Considers Splitting Basic & Green Materials Unit
Mitsui Chemicals has announced it is considering splitting off its Basic & Green Materials (B&GM) business.
Honeywell to Acquire Johnson Matthey's Catalyst Technologies Business
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
Nova Chemicals Commissions Polyethylene Film Recycling Facility in US
Nova Chemicals commissions its first polyethylene (PE) film mechanical recycling facility in Connersville, IN, US.
Relocation of Chemicals Production Footprint in Full Swing
A new Horváth study based on interviews with CxOs of Europe’s top chemical corporations reveals: The majority of board members expects no or only weak growth for the current year.
Pioneering End-to-End Green Chemical Production
Turn compliance into opportunity—see how data and innovation drive greener processes, lower costs, and sustainable growth in chemical manufacturing.
Bioeconomy Horizons: Transforming the Chemical Industry
The bioeconomy offers the chemical industry new pathways to resilience and sustainability—even as economic and political priorities shift
Sustainable Chemistry Meets Bioeconomy: A Perfect Match
How Sustainable Innovation Can Drive Inclusive Growth in Latin America and the Caribbean
Standing Strong for Europe's Chemical Industry
Rising tariffs and regulatory changes challenge the European chemical industry, highlighting the need for resilient regional supply networks and strategic collaboration among CEFIC members.
Maximize the Potential of Spent Hydroprocessing Catalysts
A new approach is helping reduce waste, recover value, and deliver on sustainability goals.
Making Waves
Global water scarcity is now urgent due to climate change, population growth, and unsustainable practices. 700 million people could be displaced by 2030, warns UNICEF, especially in water-intensive industries like personal care, textiles, food production, and paint.
New Deal to Boost Competitiveness
The EU Green Deal has hurt Europe's industry. The Clean Industrial Deal aims to improve this, but a change of mindset at the Commission is needed.
Anchoring Plastics as the Foundation of Industry in the EU Clean Industrial Deal
Plastics Europe strongly supports the European Commission's competitiveness and decarbonization agenda and welcomes the Clean Industrial Deal.
BASF CEO Markus Kamieth Presents New Strategy
BASF will differentiate between core businesses and standalone businesses and is examining strategic options.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Flow Chemistry in Drug Discovery
For the synthesis of compounds in pharmaceutical applications, it is important to select the most appropriate flow chemistry regime and equipment based on the goals of the application.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Uncovering Potential
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Preparing for the future — TCO-optimized investments
Interview with Fernando Cruzado, Vice President and Industry Lead Chemistry, and Holger Peterkord, Senior Principal and Capex Practice Lead, Efeso Group
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Torsten Wöhr, Bachem
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Neil Jones, Aenova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
